MBX MBX Biosciences: Total Company Value-to-Revenue Ratio

Public company logo of MBX Biosciences, Inc. (MBX)

The enterprise value-to-annual revenue multiple correlates with the complexity of biomaterial transportation, where 0.00 describes the current status of the metric. MBX Biosciences Inc (MBX) establishes its technological barrier through unique endocrine peptides and patent protection. Simultaneously, the company implements ESG standards in drug production, adhering to bioethics and chemical disposal regulations. This chart helps assess the asset's market value relative to its sales.

MBX Biosciences Inc (MBX) Enterprise Value-to-Revenue Ratio: for the period 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for MBX Biosciences Inc (MBX)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental valuation:MBX Biosciences Inc MBX
Flagship merchandise of MBX Corp

This indicator determines the market value of the business, adjusted for net debt, in comparison to generated revenue. By analyzing the EV/Sales multiple, an investor assesses the premium paid for the asset's operating sales. The calculation combines market capitalization and liabilities, eliminating the influence of the financing structure on the final valuation. This chart's dynamics allow for the timely detection of overvalued quotes. For MBX Biosciences Inc (MBX), this is critical when independently developing endocrine drugs without external M&A support.

Competitor analysis for MBX Biosciences Inc

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)